JP2021517959A - カメラベースの薬物容器検査 - Google Patents
カメラベースの薬物容器検査 Download PDFInfo
- Publication number
- JP2021517959A JP2021517959A JP2020542083A JP2020542083A JP2021517959A JP 2021517959 A JP2021517959 A JP 2021517959A JP 2020542083 A JP2020542083 A JP 2020542083A JP 2020542083 A JP2020542083 A JP 2020542083A JP 2021517959 A JP2021517959 A JP 2021517959A
- Authority
- JP
- Japan
- Prior art keywords
- images
- camera device
- drug container
- series
- robot
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940079593 drug Drugs 0.000 title claims abstract description 74
- 239000003814 drug Substances 0.000 title claims abstract description 74
- 238000007689 inspection Methods 0.000 title claims abstract description 30
- 238000000034 method Methods 0.000 claims abstract description 46
- 230000008569 process Effects 0.000 claims abstract description 12
- 238000001514 detection method Methods 0.000 claims abstract description 6
- 238000012545 processing Methods 0.000 claims description 11
- 239000002131 composite material Substances 0.000 claims description 6
- 230000004044 response Effects 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 230000003213 activating effect Effects 0.000 claims 2
- 230000001678 irradiating effect Effects 0.000 claims 1
- 230000003287 optical effect Effects 0.000 claims 1
- 230000002194 synthesizing effect Effects 0.000 claims 1
- 239000002245 particle Substances 0.000 abstract description 11
- 239000000835 fiber Substances 0.000 abstract description 8
- 102000004169 proteins and genes Human genes 0.000 description 32
- 108090000623 proteins and genes Proteins 0.000 description 32
- 102000005962 receptors Human genes 0.000 description 16
- 108020003175 receptors Proteins 0.000 description 16
- 238000012377 drug delivery Methods 0.000 description 10
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 10
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 9
- 102100034980 ICOS ligand Human genes 0.000 description 9
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 7
- 108010074604 Epoetin Alfa Proteins 0.000 description 6
- 102000002265 Human Growth Hormone Human genes 0.000 description 6
- 108010000521 Human Growth Hormone Proteins 0.000 description 6
- 239000000854 Human Growth Hormone Substances 0.000 description 6
- 239000012530 fluid Substances 0.000 description 6
- 101710093458 ICOS ligand Proteins 0.000 description 5
- 230000004936 stimulating effect Effects 0.000 description 5
- 108010075944 Erythropoietin Receptors Proteins 0.000 description 4
- 102100036509 Erythropoietin receptor Human genes 0.000 description 4
- 102100021866 Hepatocyte growth factor Human genes 0.000 description 4
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 4
- 101001019455 Homo sapiens ICOS ligand Proteins 0.000 description 4
- 238000000429 assembly Methods 0.000 description 4
- 230000000712 assembly Effects 0.000 description 4
- 229940126534 drug product Drugs 0.000 description 4
- 108010067416 epoetin delta Proteins 0.000 description 4
- 229950002109 epoetin delta Drugs 0.000 description 4
- 108010081679 epoetin theta Proteins 0.000 description 4
- 229950008826 epoetin theta Drugs 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000000825 pharmaceutical preparation Substances 0.000 description 4
- 108010019673 Darbepoetin alfa Proteins 0.000 description 3
- 108010008165 Etanercept Proteins 0.000 description 3
- 108010029961 Filgrastim Proteins 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 108010084052 continuous erythropoietin receptor activator Proteins 0.000 description 3
- 108010002601 epoetin beta Proteins 0.000 description 3
- 229960004579 epoetin beta Drugs 0.000 description 3
- 108010030868 epoetin zeta Proteins 0.000 description 3
- 229950005185 epoetin zeta Drugs 0.000 description 3
- 102000044389 human CD22 Human genes 0.000 description 3
- 229960001972 panitumumab Drugs 0.000 description 3
- 238000003908 quality control method Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- ZJNLYGOUHDJHMG-UHFFFAOYSA-N 1-n,4-n-bis(5-methylhexan-2-yl)benzene-1,4-diamine Chemical compound CC(C)CCC(C)NC1=CC=C(NC(C)CCC(C)C)C=C1 ZJNLYGOUHDJHMG-UHFFFAOYSA-N 0.000 description 2
- 102000004414 Calcitonin Gene-Related Peptide Human genes 0.000 description 2
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 2
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 2
- 108090000394 Erythropoietin Proteins 0.000 description 2
- 102000003951 Erythropoietin Human genes 0.000 description 2
- 108091006020 Fc-tagged proteins Proteins 0.000 description 2
- 102100039939 Growth/differentiation factor 8 Human genes 0.000 description 2
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 2
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 2
- 108010005716 Interferon beta-1a Proteins 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 102000019223 Interleukin-1 receptor Human genes 0.000 description 2
- 108050006617 Interleukin-1 receptor Proteins 0.000 description 2
- 108010056852 Myostatin Proteins 0.000 description 2
- 108010042215 OX40 Ligand Proteins 0.000 description 2
- 108090000445 Parathyroid hormone Proteins 0.000 description 2
- 101710180553 Proprotein convertase subtilisin/kexin type 9 Proteins 0.000 description 2
- 102100038955 Proprotein convertase subtilisin/kexin type 9 Human genes 0.000 description 2
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 2
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 2
- 102000014128 RANK Ligand Human genes 0.000 description 2
- 108010025832 RANK Ligand Proteins 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 108700002718 TACI receptor-IgG Fc fragment fusion Proteins 0.000 description 2
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 2
- 102100026890 Tumor necrosis factor ligand superfamily member 4 Human genes 0.000 description 2
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 description 2
- 229940115115 aranesp Drugs 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 102000023732 binding proteins Human genes 0.000 description 2
- 108091008324 binding proteins Proteins 0.000 description 2
- 229960000106 biosimilars Drugs 0.000 description 2
- 229960003735 brodalumab Drugs 0.000 description 2
- 229960003115 certolizumab pegol Drugs 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 229960001251 denosumab Drugs 0.000 description 2
- 229940073621 enbrel Drugs 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229940089118 epogen Drugs 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 230000010437 erythropoiesis Effects 0.000 description 2
- 229940105423 erythropoietin Drugs 0.000 description 2
- 229960004177 filgrastim Drugs 0.000 description 2
- 229950004896 ganitumab Drugs 0.000 description 2
- 229960003297 gemtuzumab ozogamicin Drugs 0.000 description 2
- 229960001743 golimumab Drugs 0.000 description 2
- 238000005286 illumination Methods 0.000 description 2
- 102000006495 integrins Human genes 0.000 description 2
- 108010044426 integrins Proteins 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229960001046 methoxy polyethylene glycol-epoetin beta Drugs 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229960003301 nivolumab Drugs 0.000 description 2
- 108010044644 pegfilgrastim Proteins 0.000 description 2
- 229960002087 pertuzumab Drugs 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000003672 processing method Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 229960004641 rituximab Drugs 0.000 description 2
- 229960004532 somatropin Drugs 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 229960005267 tositumomab Drugs 0.000 description 2
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 2
- RTQWWZBSTRGEAV-PKHIMPSTSA-N 2-[[(2s)-2-[bis(carboxymethyl)amino]-3-[4-(methylcarbamoylamino)phenyl]propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound CNC(=O)NC1=CC=C(C[C@@H](CN(CC(C)N(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)C=C1 RTQWWZBSTRGEAV-PKHIMPSTSA-N 0.000 description 1
- HPNRHPKXQZSDFX-UHFFFAOYSA-N 2-[[2-[[2-[[2-[[2-[[6-amino-2-[[52-[[2-[[2-[[2-[[5-amino-2-[[2-[[2-[[6-amino-2-[[1-(2-amino-3-hydroxypropanoyl)pyrrolidine-2-carbonyl]amino]hexanoyl]amino]-4-methylsulfanylbutanoyl]amino]-3-methylbutanoyl]amino]-5-oxopentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-40-(4-aminobutyl)-49-benzyl-28-butan-2-yl-31,43-bis(3-carbamimidamidopropyl)-34-(carboxymethyl)-16,19,22,25-tetrakis(hydroxymethyl)-10-(2-methylpropyl)-37-(2-methylsulfanylethyl)-6,9,12,15,18,21,24,27,30,33,36,39,42,45,48,51-hexadecaoxo-1,2-dithia-5,8,11,14,17,20,23,26,29,32,35,38,41,44,47,50-hexadecazacyclotripentacontane-4-carbonyl]amino]hexanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-imidazol-5-yl)propanoic acid Chemical compound N1C(=O)C(NC(=O)CNC(=O)C(CO)NC(=O)CNC(=O)C(CCC(N)=O)NC(=O)C(NC(=O)C(CCSC)NC(=O)C(CCCCN)NC(=O)C2N(CCC2)C(=O)C(N)CO)C(C)C)CSSCC(C(=O)NC(CCCCN)C(=O)NC(C(C)C)C(=O)NC(CC(C)C)C(=O)NC(CCCNC(N)=N)C(=O)NC(CCCNC(N)=N)C(=O)NC(CC=2N=CNC=2)C(O)=O)NC(=O)CNC(=O)C(CC(C)C)NC(=O)CNC(=O)C(CO)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(C(C)CC)NC(=O)C(CCCNC(N)=N)NC(=O)C(CC(O)=O)NC(=O)C(CCSC)NC(=O)C(CCCCN)NC(=O)C(CCCNC(N)=N)NC(=O)CNC(=O)C1CC1=CC=CC=C1 HPNRHPKXQZSDFX-UHFFFAOYSA-N 0.000 description 1
- MZZYGYNZAOVRTG-UHFFFAOYSA-N 2-hydroxy-n-(1h-1,2,4-triazol-5-yl)benzamide Chemical compound OC1=CC=CC=C1C(=O)NC1=NC=NN1 MZZYGYNZAOVRTG-UHFFFAOYSA-N 0.000 description 1
- MJZJYWCQPMNPRM-UHFFFAOYSA-N 6,6-dimethyl-1-[3-(2,4,5-trichlorophenoxy)propoxy]-1,6-dihydro-1,3,5-triazine-2,4-diamine Chemical compound CC1(C)N=C(N)N=C(N)N1OCCCOC1=CC(Cl)=C(Cl)C=C1Cl MJZJYWCQPMNPRM-UHFFFAOYSA-N 0.000 description 1
- ZKRFOXLVOKTUTA-KQYNXXCUSA-N 9-(5-phosphoribofuranosyl)-6-mercaptopurine Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(NC=NC2=S)=C2N=C1 ZKRFOXLVOKTUTA-KQYNXXCUSA-N 0.000 description 1
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- 102100034608 Angiopoietin-2 Human genes 0.000 description 1
- 101100067974 Arabidopsis thaliana POP2 gene Proteins 0.000 description 1
- 102100038080 B-cell receptor CD22 Human genes 0.000 description 1
- 101800000407 Brain natriuretic peptide 32 Proteins 0.000 description 1
- 229960005509 CAT-3888 Drugs 0.000 description 1
- 229940124296 CD52 monoclonal antibody Drugs 0.000 description 1
- 229940045513 CTLA4 antagonist Drugs 0.000 description 1
- 101100381481 Caenorhabditis elegans baz-2 gene Proteins 0.000 description 1
- 101100179591 Caenorhabditis elegans ins-22 gene Proteins 0.000 description 1
- 108090000932 Calcitonin Gene-Related Peptide Proteins 0.000 description 1
- 102000014468 Calcitonin Gene-Related Peptide Receptors Human genes 0.000 description 1
- 108010078311 Calcitonin Gene-Related Peptide Receptors Proteins 0.000 description 1
- 102000009410 Chemokine receptor Human genes 0.000 description 1
- 108050000299 Chemokine receptor Proteins 0.000 description 1
- 241000193163 Clostridioides difficile Species 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 102100038497 Cytokine receptor-like factor 2 Human genes 0.000 description 1
- 101710194733 Cytokine receptor-like factor 2 Proteins 0.000 description 1
- 101710158332 Diuretic hormone Proteins 0.000 description 1
- 101710204261 Diuretic hormone class 2 Proteins 0.000 description 1
- 102000001301 EGF receptor Human genes 0.000 description 1
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 description 1
- 102400000322 Glucagon-like peptide 1 Human genes 0.000 description 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 1
- 101000924533 Homo sapiens Angiopoietin-2 Proteins 0.000 description 1
- 101000741445 Homo sapiens Calcitonin Proteins 0.000 description 1
- 101100118549 Homo sapiens EGFR gene Proteins 0.000 description 1
- 101000599940 Homo sapiens Interferon gamma Proteins 0.000 description 1
- 101001010568 Homo sapiens Interleukin-11 Proteins 0.000 description 1
- 101000669513 Homo sapiens Metalloproteinase inhibitor 1 Proteins 0.000 description 1
- 101001098868 Homo sapiens Proprotein convertase subtilisin/kexin type 9 Proteins 0.000 description 1
- 101000845170 Homo sapiens Thymic stromal lymphopoietin Proteins 0.000 description 1
- 101000830603 Homo sapiens Tumor necrosis factor ligand superfamily member 11 Proteins 0.000 description 1
- 101000610604 Homo sapiens Tumor necrosis factor receptor superfamily member 10B Proteins 0.000 description 1
- 101000851018 Homo sapiens Vascular endothelial growth factor receptor 1 Proteins 0.000 description 1
- 102000038455 IGF Type 1 Receptor Human genes 0.000 description 1
- 108010031794 IGF Type 1 Receptor Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000016844 Immunoglobulin-like domains Human genes 0.000 description 1
- 108050006430 Immunoglobulin-like domains Proteins 0.000 description 1
- 108010078049 Interferon alpha-2 Proteins 0.000 description 1
- 108010005714 Interferon beta-1b Proteins 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 description 1
- 108700021006 Interleukin-1 receptor antagonist Proteins 0.000 description 1
- 102000013264 Interleukin-23 Human genes 0.000 description 1
- 108010065637 Interleukin-23 Proteins 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 102000010787 Interleukin-4 Receptors Human genes 0.000 description 1
- 108010038486 Interleukin-4 Receptors Proteins 0.000 description 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 description 1
- 102100026261 Metalloproteinase inhibitor 3 Human genes 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000003982 Parathyroid hormone Human genes 0.000 description 1
- 102100036893 Parathyroid hormone Human genes 0.000 description 1
- 102000008022 Proto-Oncogene Proteins c-met Human genes 0.000 description 1
- 108010089836 Proto-Oncogene Proteins c-met Proteins 0.000 description 1
- 101100372762 Rattus norvegicus Flt1 gene Proteins 0.000 description 1
- 101100123851 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) HER1 gene Proteins 0.000 description 1
- 102100034201 Sclerostin Human genes 0.000 description 1
- 108050006698 Sclerostin Proteins 0.000 description 1
- 101710084578 Short neurotoxin 1 Proteins 0.000 description 1
- 206010041925 Staphylococcal infections Diseases 0.000 description 1
- 102100034196 Thrombopoietin receptor Human genes 0.000 description 1
- 101710148535 Thrombopoietin receptor Proteins 0.000 description 1
- 102100031294 Thymic stromal lymphopoietin Human genes 0.000 description 1
- 108010031429 Tissue Inhibitor of Metalloproteinase-3 Proteins 0.000 description 1
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
- 108050006955 Tissue-type plasminogen activator Proteins 0.000 description 1
- 101710182532 Toxin a Proteins 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 102100040112 Tumor necrosis factor receptor superfamily member 10B Human genes 0.000 description 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 1
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 229940119059 actemra Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229940099983 activase Drugs 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 229960002964 adalimumab Drugs 0.000 description 1
- 229950009084 adecatumumab Drugs 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 229960000548 alemtuzumab Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000002391 anti-complement effect Effects 0.000 description 1
- 230000001494 anti-thymocyte effect Effects 0.000 description 1
- 108010008730 anticomplement Proteins 0.000 description 1
- 229950009925 atacicept Drugs 0.000 description 1
- 229940120638 avastin Drugs 0.000 description 1
- 229940003504 avonex Drugs 0.000 description 1
- 229960004669 basiliximab Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229940022836 benlysta Drugs 0.000 description 1
- 229940021459 betaseron Drugs 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 229960003008 blinatumomab Drugs 0.000 description 1
- 229940101815 blincyto Drugs 0.000 description 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 1
- -1 but not limited to Proteins 0.000 description 1
- 229940112129 campath Drugs 0.000 description 1
- 229950007296 cantuzumab mertansine Drugs 0.000 description 1
- 108700001003 carbamylated erythropoietin Proteins 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 229940047120 colony stimulating factors Drugs 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 229960005029 darbepoetin alfa Drugs 0.000 description 1
- 238000013135 deep learning Methods 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 150000002019 disulfides Chemical class 0.000 description 1
- 229960001776 edrecolomab Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 229960003388 epoetin alfa Drugs 0.000 description 1
- 108010090921 epoetin omega Proteins 0.000 description 1
- 229950008767 epoetin omega Drugs 0.000 description 1
- 229950009760 epratuzumab Drugs 0.000 description 1
- 229940082789 erbitux Drugs 0.000 description 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
- 229960000403 etanercept Drugs 0.000 description 1
- 229960002027 evolocumab Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 229950001109 galiximab Drugs 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 239000003168 generic drug Substances 0.000 description 1
- 229940063135 genotropin Drugs 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 108010013846 hematide Proteins 0.000 description 1
- 229940022353 herceptin Drugs 0.000 description 1
- 102000049885 human IL11 Human genes 0.000 description 1
- 102000053529 human TNFSF11 Human genes 0.000 description 1
- 229940045644 human calcitonin Drugs 0.000 description 1
- 229940048921 humira Drugs 0.000 description 1
- 229960001001 ibritumomab tiuxetan Drugs 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 229940091204 imlygic Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 229940090438 infergen Drugs 0.000 description 1
- 229960000598 infliximab Drugs 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 108010010648 interferon alfacon-1 Proteins 0.000 description 1
- 229960004461 interferon beta-1a Drugs 0.000 description 1
- 229960001388 interferon-beta Drugs 0.000 description 1
- 229960005386 ipilimumab Drugs 0.000 description 1
- 229940054136 kineret Drugs 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 229940087875 leukine Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 229940076783 lucentis Drugs 0.000 description 1
- KHPKQFYUPIUARC-UHFFFAOYSA-N lumiracoxib Chemical compound OC(=O)CC1=CC(C)=CC=C1NC1=C(F)C=CC=C1Cl KHPKQFYUPIUARC-UHFFFAOYSA-N 0.000 description 1
- 229960000994 lumiracoxib Drugs 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 description 1
- 229940029238 mircera Drugs 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229950000720 moxetumomab pasudotox Drugs 0.000 description 1
- 229960003816 muromonab-cd3 Drugs 0.000 description 1
- ONDPWWDPQDCQNJ-UHFFFAOYSA-N n-(3,3-dimethyl-1,2-dihydroindol-6-yl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide;phosphoric acid Chemical compound OP(O)(O)=O.OP(O)(O)=O.C=1C=C2C(C)(C)CNC2=CC=1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 ONDPWWDPQDCQNJ-UHFFFAOYSA-N 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- 229940054205 natrecor Drugs 0.000 description 1
- 229940071846 neulasta Drugs 0.000 description 1
- 229940082926 neumega Drugs 0.000 description 1
- 229940029345 neupogen Drugs 0.000 description 1
- 229950010203 nimotuzumab Drugs 0.000 description 1
- 229960002450 ofatumumab Drugs 0.000 description 1
- 229950008516 olaratumab Drugs 0.000 description 1
- 230000000174 oncolytic effect Effects 0.000 description 1
- 108010046821 oprelvekin Proteins 0.000 description 1
- 229950007283 oregovomab Drugs 0.000 description 1
- 229940035567 orencia Drugs 0.000 description 1
- 229940029358 orthoclone okt3 Drugs 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000000199 parathyroid hormone Substances 0.000 description 1
- 229960001319 parathyroid hormone Drugs 0.000 description 1
- HQQSBEDKMRHYME-UHFFFAOYSA-N pefloxacin mesylate Chemical compound [H+].CS([O-])(=O)=O.C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCN(C)CC1 HQQSBEDKMRHYME-UHFFFAOYSA-N 0.000 description 1
- 229960001373 pegfilgrastim Drugs 0.000 description 1
- 108010048732 pegylated erythropoietin Proteins 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229940071643 prefilled syringe Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000004801 process automation Methods 0.000 description 1
- 229940029359 procrit Drugs 0.000 description 1
- 229940092597 prolia Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 229940107685 reopro Drugs 0.000 description 1
- 108010038379 sargramostim Proteins 0.000 description 1
- 229940115586 simulect Drugs 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229940055944 soliris Drugs 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 229940036185 synagis Drugs 0.000 description 1
- 229940120982 tarceva Drugs 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 229940126672 traditional medicines Drugs 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 229960003824 ustekinumab Drugs 0.000 description 1
- 229940099039 velcade Drugs 0.000 description 1
- 229940014556 xgeva Drugs 0.000 description 1
- 229940099073 xolair Drugs 0.000 description 1
- 229950008250 zalutumumab Drugs 0.000 description 1
- 229950009002 zanolimumab Drugs 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/84—Systems specially adapted for particular applications
- G01N21/88—Investigating the presence of flaws or contamination
- G01N21/90—Investigating the presence of flaws or contamination in a container or its contents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/84—Systems specially adapted for particular applications
- G01N21/88—Investigating the presence of flaws or contamination
- G01N21/90—Investigating the presence of flaws or contamination in a container or its contents
- G01N21/9009—Non-optical constructional details affecting optical inspection, e.g. cleaning mechanisms for optical parts, vibration reduction
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/84—Systems specially adapted for particular applications
- G01N21/88—Investigating the presence of flaws or contamination
- G01N21/90—Investigating the presence of flaws or contamination in a container or its contents
- G01N21/9018—Dirt detection in containers
Landscapes
- General Health & Medical Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Investigating Materials By The Use Of Optical Means Adapted For Particular Applications (AREA)
Abstract
Description
その内容全体が参照により本明細書に組み込まれる、2018年3月30日に出願された米国仮特許出願第62/650,554号明細書に対する優先権を主張する。
Claims (20)
- 異物特定のための薬物容器用検査システムであって、
レンズを含むカメラデバイスと、
直線経路に沿って移動可能な一部分を有するロボットであって、前記カメラデバイスは、前記ロボットが前記直線経路に沿った前記カメラデバイスと前記薬物容器との間の相対移動を生じさせる間、前記カメラデバイスが前記薬物容器の側壁及び/又は底壁の内部表面の一連の画像を捕らえるように構成されるように、前記薬物容器の長手方向軸と位置合わせされている、ロボットと、
前記カメラデバイスと通信する制御回路であって、プロセッサと、メモリと、前記メモリに格納されており、前記カメラデバイスから前記一連の画像を受信し、前記一連の画像を処理し、前記画像内に示される異物を特定するために前記プロセッサにより実行可能なロジックと、を含む、制御回路と、
を含む、検査システム。 - 前記レンズは、テレセントリックレンズ又は360°光学系を含む、請求項1に記載の検査システム。
- 前記レンズの絞りは最大設定に開放される、請求項1又は2に記載の検査システム。
- 前記ロボットの前記一部分は垂直部分を含み、前記ロボットは、前記カメラデバイスを薬物容器の列に沿って移動させるように構成された深さ部分と、前記カメラデバイスを薬物容器の隣接する列にわたって移動させるように構成された幅部分と、を更に含む、請求項1〜3のいずれか一項に記載の検査システム。
- 前記ロジックは更に、前記ロボットを動作させるために前記プロセッサにより実行可能である、請求項1〜4のいずれか一項に記載の検査システム。
- 前記一連の画像を処理し、前記画像内に示される異物を特定するために前記プロセッサにより実行可能な前記ロジックは、前記一連の画像のうちの特定の画像を、前記特定の画像の直前又は直後に撮影された少なくとも1つの画像と比較し、差を特定するために前記プロセッサにより実行可能な前記ロジックを含む、請求項1に記載の検査システム。
- 前記一連の画像を処理し、前記画像内に示される異物を特定するために前記プロセッサにより実行可能な前記ロジックは、異物を特定するために、前記一連の画像を、前記薬物容器の前記側壁の前記内部表面の全てを焦点を合わせた状態で示す合成画像に合成するために前記プロセッサにより実行可能な前記ロジックを含む、請求項1に記載の検査システム。
- 前記薬物容器に光を照射し、前記カメラデバイスの被写界深度内の前記薬物容器の一部分を照明するように方向付けられた光源を更に含む、請求項1〜7のいずれか一項に記載の検査システム。
- 前記光源は前記薬物容器に沿って移動可能であり、それにより、前記カメラデバイスを前記直線経路に沿って移動させる際、前記カメラデバイスの被写界深度内の前記薬物容器の一部分を照明する、請求項8に記載の検査システム。
- 前記光源は複数の光源を含み、前記複数の光源のそれぞれは、前記薬物容器の一部分を照明するように方向付けられている、請求項8に記載の検査システム。
- 薬物容器の異物を検査する方法であって、
カメラデバイスを薬物容器の長手方向軸に沿って方向付けることと、
前記カメラデバイス又は前記薬物容器を前記長手方向軸に沿って移動させることと、
前記薬物容器の側壁の内部表面の一連の画像を捕らえるために前記カメラデバイスを動作させることと、
前記一連の画像内に示される異物を特定するために前記一連の画像を制御回路で処理することと、
を含む、方法。 - ロボットを、前記ロボットの一部分を直線経路に沿って移動させるように動作させることを含む、前記カメラデバイスを前記長手方向軸に沿って移動させることを含み、前記カメラデバイスは前記ロボットの前記一部分に結合されている、請求項11に記載の方法。
- 深さ部分によって前記カメラデバイスを薬物容器の列に沿って移動させるように前記ロボットを動作させることと、幅部分によって前記カメラデバイスを薬物容器の隣接する列に移動させるように前記ロボットを動作させることと、を更に含む、請求項12に記載の方法。
- 前記カメラデバイスを動作させること及び前記ロボットを動作させることは、前記薬物容器の前記側壁の前記内部表面の前記一連の画像を生成するために、前記制御回路で前記カメラデバイス及び前記ロボットを同時に動作させることを含む、請求項12又は13に記載の方法。
- 前記一連の画像を処理することは、前記一連の画像のうちの特定の画像を、前記特定の画像の直前又は直後に撮影された少なくとも1つの画像と比較し、差を特定することを含む、請求項11に記載の方法。
- 前記一連の画像を処理することは、異物を特定するために、前記一連の画像を、前記薬物容器の前記側壁の前記内部表面の全てを焦点を合わせた状態で示す合成画像に合成することを含む、請求項11に記載の方法。
- 前記一連の画像内における異物の特定に応答して前記制御回路で検出信号を送信することを更に含む、請求項11に記載の方法。
- 前記薬物容器に光を照射し、前記カメラデバイスの被写界深度内の前記薬物容器の一部分を照明するように光源を動作させることを更に含む、請求項11〜17のいずれか一項に記載の方法。
- 前記長手方向軸に沿った前記カメラデバイスの移動に対応して、前記薬物容器の高さに沿って前記光源を移動させることを更に含む、請求項18に記載の方法。
- 前記光源を動作させることは、複数の光源を動作させることを含み、前記複数の光源のそれぞれは、前記薬物容器の一部分を照明するように方向付けられている、請求項18に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862650554P | 2018-03-30 | 2018-03-30 | |
US62/650,554 | 2018-03-30 | ||
PCT/US2019/017602 WO2019190647A1 (en) | 2018-03-30 | 2019-02-12 | Camera-based drug container inspection |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2021517959A true JP2021517959A (ja) | 2021-07-29 |
JP7476105B2 JP7476105B2 (ja) | 2024-04-30 |
Family
ID=65529829
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020542083A Active JP7476105B2 (ja) | 2018-03-30 | 2019-02-12 | カメラベースの薬物容器検査 |
Country Status (12)
Country | Link |
---|---|
US (1) | US11499922B2 (ja) |
EP (1) | EP3775857B1 (ja) |
JP (1) | JP7476105B2 (ja) |
CN (1) | CN111788475A (ja) |
AU (1) | AU2019244189B2 (ja) |
CA (1) | CA3092560A1 (ja) |
ES (1) | ES2956287T3 (ja) |
IL (1) | IL276335B2 (ja) |
MA (1) | MA52168A (ja) |
PL (1) | PL3775857T3 (ja) |
SG (1) | SG11202007756XA (ja) |
WO (1) | WO2019190647A1 (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102547723B1 (ko) * | 2018-06-29 | 2023-06-27 | 주식회사 고영테크놀러지 | 플리퍼 장치 및 이를 이용한 대상물 검사방법 |
CA3159206A1 (en) * | 2019-11-15 | 2021-05-20 | Amgen Inc. | Offline troubleshooting and development for automated visual inspection stations |
CN112925351B (zh) * | 2019-12-06 | 2022-08-02 | 杭州萤石软件有限公司 | 一种视觉机器光源控制方法、装置 |
IT202100007718A1 (it) * | 2021-03-29 | 2022-09-29 | S A T S R L | Metodo per ispezionare automaticamente un prodotto e relativo sistema |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010128384A1 (en) * | 2009-05-07 | 2010-11-11 | Brevetti C.E.A. S.P.A. | Machine for inspecting containers and inspection method employing said machine |
JP2016205929A (ja) * | 2015-04-20 | 2016-12-08 | 凸版印刷株式会社 | 異物判別装置および異物判別方法 |
US20170124704A1 (en) * | 2014-06-10 | 2017-05-04 | Siemens Healthcare Diagnostics Inc. | Drawer vision system |
JP2021514466A (ja) * | 2018-02-20 | 2021-06-10 | プレスコ テクノロジー インコーポレーテッドPressco Technology Inc. | 飲料缶のカラー装飾仕様をオンラインで監視および制御するための方法とシステム |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3529167A (en) * | 1967-08-16 | 1970-09-15 | Automatic Sprinkler Corp | Container inspection apparatus with nutating instantaneous field of observation |
US3690456A (en) * | 1971-06-25 | 1972-09-12 | Powers Manufacturing | Glass container crack detector |
US4262196A (en) * | 1979-07-09 | 1981-04-14 | Barry-Wehmiller Company | Container inspection apparatus |
US4731649A (en) * | 1986-09-11 | 1988-03-15 | Vistech Corp. | Oblique illumination for video rim inspection |
CH670891A5 (ja) * | 1986-10-10 | 1989-07-14 | Elpatronic Ag | |
US4874940A (en) * | 1988-01-11 | 1989-10-17 | Brockway, Inc. (N.Y.) | Method and apparatus for inspection of a transparent container |
JP3091988B2 (ja) * | 1993-01-04 | 2000-09-25 | 信越化学工業株式会社 | 樹脂粉末の可塑剤吸収量自動測定装置 |
US5466927A (en) * | 1994-04-08 | 1995-11-14 | Owens-Brockway Glass Container Inc. | Inspection of translucent containers |
DE19605133C2 (de) * | 1996-02-13 | 2000-06-15 | Krones Ag | Inspektionsmaschine für Gefäße |
US6275287B1 (en) * | 1998-04-25 | 2001-08-14 | Nihon Yamamura Glass Co., Ltd. | Check detector for glass bottle neck and finish portion |
PT1425389E (pt) | 2001-08-23 | 2012-02-07 | Genmab As | Anticorpos humanos específicos para interleucina 15 (il-15) |
EP1563283A2 (en) * | 2002-11-08 | 2005-08-17 | Pressco Technology, Inc. | System and method for associating container defect information to a specific path of manufacturing |
JP2005017003A (ja) | 2003-06-24 | 2005-01-20 | Sukiyan Technol:Kk | バイアルの検査システム |
EP1630550A1 (en) * | 2004-08-27 | 2006-03-01 | Moller & Devicon A/S | Methods and apparatuses of detecting foreign particles or faults in a plurality of filled containers |
US20070084763A1 (en) * | 2005-10-18 | 2007-04-19 | Stephenson Michael B | Foreign matter detection system and method |
DE102006053673A1 (de) * | 2006-11-13 | 2008-05-15 | Khs Ag | Verfahren zur Inspektion von Flaschen oder dergleichen Behälter sowie Messstation für eine Inspektions- oder Kontrollstrecke für Flaschen oder dergleichen Behälter |
CN101105460A (zh) * | 2007-05-15 | 2008-01-16 | 广州市万世德包装机械有限公司 | 多功能验瓶机 |
EP2352012A4 (en) * | 2008-11-20 | 2014-05-21 | Asahi Glass Co Ltd | DEVICE FOR CONTROLLING TRANSPARENT BODIES |
JP2012026858A (ja) | 2010-07-23 | 2012-02-09 | Nippon Steel Corp | 円筒容器の内周面検査装置 |
DE102010032410B4 (de) * | 2010-07-27 | 2014-11-13 | Mall + Herlan Schweiz Ag | Inspektionsvorrichtung, Fertigungsanlage mit Inspektionsvorrichtung und Inspektionsverfahren für Gefäße |
JP5633005B2 (ja) | 2010-08-20 | 2014-12-03 | キリンテクノシステム株式会社 | 異物検査装置 |
US9188545B2 (en) * | 2011-10-28 | 2015-11-17 | Owens-Brockway Glass Container Inc. | Container inspection apparatus and method |
US10132736B2 (en) * | 2012-05-24 | 2018-11-20 | Abbvie Inc. | Methods for inspection of protein particles in a liquid beneficial agent |
IL226111A (en) * | 2013-05-02 | 2015-11-30 | D I R Technologies Detection Ir Ltd | Thermography-based method, device and product to identify defects in sealing that includes a conductive internal gasket |
CN103308527B (zh) * | 2013-05-30 | 2015-02-11 | 屈桢深 | 输液瓶内异物的检测方法及检测系统 |
AU2015271676A1 (en) * | 2014-06-03 | 2016-11-10 | Amgen Inc. | Devices and methods for assisting a user of a drug delivery device |
CN107408520B (zh) * | 2015-03-03 | 2022-02-25 | 卢茨·瑞布斯道克 | 检查系统 |
-
2019
- 2019-02-12 EP EP19707575.7A patent/EP3775857B1/en active Active
- 2019-02-12 PL PL19707575.7T patent/PL3775857T3/pl unknown
- 2019-02-12 MA MA052168A patent/MA52168A/fr unknown
- 2019-02-12 AU AU2019244189A patent/AU2019244189B2/en active Active
- 2019-02-12 SG SG11202007756XA patent/SG11202007756XA/en unknown
- 2019-02-12 JP JP2020542083A patent/JP7476105B2/ja active Active
- 2019-02-12 CN CN201980016058.6A patent/CN111788475A/zh active Pending
- 2019-02-12 US US16/977,025 patent/US11499922B2/en active Active
- 2019-02-12 WO PCT/US2019/017602 patent/WO2019190647A1/en active Application Filing
- 2019-02-12 ES ES19707575T patent/ES2956287T3/es active Active
- 2019-02-12 CA CA3092560A patent/CA3092560A1/en active Pending
-
2020
- 2020-07-28 IL IL276335A patent/IL276335B2/en unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010128384A1 (en) * | 2009-05-07 | 2010-11-11 | Brevetti C.E.A. S.P.A. | Machine for inspecting containers and inspection method employing said machine |
US20170124704A1 (en) * | 2014-06-10 | 2017-05-04 | Siemens Healthcare Diagnostics Inc. | Drawer vision system |
JP2016205929A (ja) * | 2015-04-20 | 2016-12-08 | 凸版印刷株式会社 | 異物判別装置および異物判別方法 |
JP2021514466A (ja) * | 2018-02-20 | 2021-06-10 | プレスコ テクノロジー インコーポレーテッドPressco Technology Inc. | 飲料缶のカラー装飾仕様をオンラインで監視および制御するための方法とシステム |
Also Published As
Publication number | Publication date |
---|---|
SG11202007756XA (en) | 2020-09-29 |
IL276335B2 (en) | 2023-05-01 |
ES2956287T3 (es) | 2023-12-18 |
MA52168A (fr) | 2021-02-17 |
JP7476105B2 (ja) | 2024-04-30 |
WO2019190647A1 (en) | 2019-10-03 |
IL276335B1 (en) | 2023-01-01 |
AU2019244189B2 (en) | 2024-04-04 |
CN111788475A (zh) | 2020-10-16 |
EP3775857B1 (en) | 2023-07-05 |
US20210010946A1 (en) | 2021-01-14 |
PL3775857T3 (pl) | 2024-01-29 |
US11499922B2 (en) | 2022-11-15 |
AU2019244189A1 (en) | 2020-08-13 |
EP3775857A1 (en) | 2021-02-17 |
CA3092560A1 (en) | 2019-10-03 |
IL276335A (en) | 2020-09-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7476105B2 (ja) | カメラベースの薬物容器検査 | |
TW201507746A (zh) | 注射器及其組裝方式 | |
JP2022519132A (ja) | 投薬システム及び手法 | |
US20240157057A1 (en) | Sound-detection based injection time measurement system for drug delivery devices | |
EP4327056A1 (en) | Methods and systems for automated syringe quality evaluation | |
US20240115462A1 (en) | High-throughput automated reconstitution of lyophilized drug product | |
CA3228140A1 (en) | Apparatuses, systems and methods for plunger-stopper depth measurement in pre-filled syringes | |
US20240082110A1 (en) | Coaxial needle adapter and guide bracket for robotic liquid handling platform | |
WO2023287562A1 (en) | Systems and approaches for drug processing single-use hardware | |
US20240103025A1 (en) | Systems and approaches for drug processing | |
US20230173198A1 (en) | Drug delivery member insertion sensing assemblies, drug delivery devices, and related methods | |
US20220265975A1 (en) | Light-activated ultrasonic delivery and manipulation of liquid medication from a drug reservoir | |
CA3235966A1 (en) | Plunger rod removal force method and fixture | |
WO2023196111A1 (en) | Packaging for drug delivery device | |
WO2024049793A1 (en) | System and method of limiting subvisible particles in a syringe | |
WO2022055761A1 (en) | Inline uv flow device for sterilizing flow cytometry sheath fluid |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220210 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230404 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230628 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230925 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20231212 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240311 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240326 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240417 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7476105 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |